TY - JOUR
T1 - The routine clinical use of pharmacogenetic tests: what it will require?
AU - Dias, Mafalda
AU - Sorich, Michael
AU - Rowland, Andrew
AU - Wiese, Michael
AU - McKinnon, Ross
PY - 2017/8
Y1 - 2017/8
N2 - Pharmacogenetic testing aims to personalize drug therapy with a view to optimising drug efficacy and minimise toxicity. However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. Widespread integration into routine clinical practice has been limited by a complex set of issues including regulatory and reimbursement frameworks, evidence of clinical utility and clinician perspectives, practices and education. Here we assess the current barriers to widespread clinical uptake and identify the key issue necessary to address to accelerate routine testing.
AB - Pharmacogenetic testing aims to personalize drug therapy with a view to optimising drug efficacy and minimise toxicity. However, despite the potential benefits, pharmacogenetic testing is mostly confined to specialised medical areas, laboratories and centres. Widespread integration into routine clinical practice has been limited by a complex set of issues including regulatory and reimbursement frameworks, evidence of clinical utility and clinician perspectives, practices and education. Here we assess the current barriers to widespread clinical uptake and identify the key issue necessary to address to accelerate routine testing.
KW - biomarkers
KW - clinical uptake
KW - diagnostic tests
KW - personalized medicine
UR - http://www.scopus.com/inward/record.url?scp=85013784311&partnerID=8YFLogxK
U2 - 10.1007/s11095-017-2128-0
DO - 10.1007/s11095-017-2128-0
M3 - Review article
SN - 0724-8741
VL - 34
SP - 1544
EP - 1550
JO - PHARMACEUTICAL RESEARCH
JF - PHARMACEUTICAL RESEARCH
IS - 8
ER -